MODERNA INC. DL-_0001
Commented by Carsten Mainitz on January 12th, 2021 | 10:28 CET
CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!
The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.
Read
Commented by André Will-Laudien on December 23rd, 2020 | 08:50 CET
Q & M Dental, Moderna, AstraZeneca: Serving people!
Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.
Read
Commented by Stefan Feulner on December 15th, 2020 | 15:37 CET
Moderna, AdTiger, AstraZeneca - here we go!
The announcement of the second lockdown last Sunday is a disaster for brick-and-mortar retailers. After an extremely sluggish Christmas season so far, the new closures will turn off the lights for stores during the most critical time of the year. Of the total 560,000 jobs in downtown retail, up to 250,000 are said to be acutely threatened. The beneficiary of this disastrous situation is once again, eCommerce. However, in addition to the major platforms Amazon, Alibaba or Zalando, other Internet companies are also profiting from the online trend.
Read
Commented by Nico Popp on December 9th, 2020 | 14:16 CET
Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?
The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.
Read
Commented by Stefan Feulner on November 25th, 2020 | 11:15 CET
Moderna, Triumph Gold, BioNTech - bet on winners!
Gold has not made it out - for the time being. Due to the decision of the Americans pro Joe Biden and the very successful developments regarding a vaccine against the coronavirus, the precious yellow metal went downhill for the time being. The correction may well continue a little further. However, in the past, these setbacks were lucrative with anti-cyclical entry opportunities. Therefore, one should use the time now to take a closer look at promising gold mines.
Read
Commented by Stefan Feulner on November 20th, 2020 | 11:20 CET
BioNTech, Saturn Oil & Gas, Moderna - these stocks will explode!
Now it's all happening at once with the news in the race against the Corona pandemic. According to BioNTech and its US competitor Moderna, first deliveries of the vaccine are scheduled for the end of this year and the start of 2021. The first step towards normality, even though the head of BioNTech, Ugur Sahin, does not expect a normal social life until the end of 2021 at the earliest. Then, if everything goes smoothly, badly shaken industries should experience an unprecedented renaissance, and their share prices should take off.
Read
Commented by Stefan Feulner on November 17th, 2020 | 09:58 CET
BYD, Upco International, Moderna: bet on the winners!
Who will win the race for the fastest and best vaccine against the Coronavirus? After the first test results, specific trends are emerging. It is clear now, driven by news, large fluctuations and thus high price gains are possible. The overall stock market seems not to care about this, just that a vaccine will be available soon, is enough. After a short correction, the trend goes south again. The market could see significantly higher prices next year.
Read
Commented by Nico Popp on September 4th, 2020 | 09:48 CEST
Moderna, Evotec or Valeo Pharma: Who has the game changer?
The pandemic is driving the markets. But sometimes investors either come too late or bet on the wrong horse. In the analysis, three stocks for which investors hope for the game changer. The fact that the search for a cure for Covid-19 is making high waves on the stock market is shown by stocks like Moderna. Despite the current price correction, the biotech company from the USA achieves an annual performance of a massive 280%. The reason for this soaring performance is easy to find: Moderna is researching a Corona vaccine and has already reported promising interim results. Among other things, the EU has already secured several million vaccine doses in the event of a successful clinical approval procedure.
Read
Commented by Mario Hose on June 2nd, 2020 | 05:58 CEST
Memphasys, Moderna, Paion - Investments in solutions with potential
Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.
Read